Study of protective activity of recombinant tuberculosis pathogen antigens in mice
The article is devoted to the analysis of the current situation on the development of new vaccines against tuberculosis. The shortcomings of the traditional BCG vaccine are well known. The low efficacy and relatively high reactogenicity of this vaccine led to the abolition of BCG in some highly developed countries with low incidence. Most of the new vaccines developed contain ESAT-6 and CFP-10 antigen proteins, whose immunological properties are discussed in this paper.